Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Ganitumab in Ewing Sarcoma
NCT04129151Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ganitumab, palbociclib in Ewing sarcoma, sponsored by Dana-Farber Cancer Institute. Started Dec 2019; status: terminated.
02
Drugs
ganitumabpalbociclib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT04129151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129151.